Logo image of NURO

NEUROMETRIX INC (NURO) Stock Fundamental Analysis

NASDAQ:NURO - Nasdaq - US6412558800 - Common Stock - Currency: USD

4.3875  -0.03 (-0.74%)

Fundamental Rating

2

Overall NURO gets a fundamental rating of 2 out of 10. We evaluated NURO against 190 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NURO as it has an excellent financial health rating, but there are worries on the profitability. NURO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NURO had negative earnings in the past year.
In the past year NURO has reported a negative cash flow from operations.
In the past 5 years NURO always reported negative net income.
NURO had a negative operating cash flow in each of the past 5 years.
NURO Yearly Net Income VS EBIT VS OCF VS FCFNURO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of NURO (-44.65%) is worse than 63.83% of its industry peers.
Looking at the Return On Equity, with a value of -48.03%, NURO is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
ROA -44.65%
ROE -48.03%
ROIC N/A
ROA(3y)-19.18%
ROA(5y)-27.69%
ROE(3y)-20.41%
ROE(5y)-50.01%
ROIC(3y)N/A
ROIC(5y)N/A
NURO Yearly ROA, ROE, ROICNURO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

1.3 Margins

NURO has a Gross Margin (57.56%) which is in line with its industry peers.
In the last couple of years the Gross Margin of NURO has grown nicely.
NURO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.03%
GM growth 5Y7.84%
NURO Yearly Profit, Operating, Gross MarginsNURO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

7

2. Health

2.1 Basic Checks

NURO does not have a ROIC to compare to the WACC, probably because it is not profitable.
NURO has less shares outstanding than it did 1 year ago.
NURO has more shares outstanding than it did 5 years ago.
NURO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NURO Yearly Shares OutstandingNURO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
NURO Yearly Total Debt VS Total AssetsNURO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -13.52, we must say that NURO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NURO (-13.52) is worse than 82.98% of its industry peers.
There is no outstanding debt for NURO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.52
ROIC/WACCN/A
WACC9.06%
NURO Yearly LT Debt VS Equity VS FCFNURO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 13.88 indicates that NURO has no problem at all paying its short term obligations.
NURO has a Current ratio of 13.88. This is amongst the best in the industry. NURO outperforms 97.34% of its industry peers.
A Quick Ratio of 12.70 indicates that NURO has no problem at all paying its short term obligations.
NURO's Quick ratio of 12.70 is amongst the best of the industry. NURO outperforms 97.34% of its industry peers.
Industry RankSector Rank
Current Ratio 13.88
Quick Ratio 12.7
NURO Yearly Current Assets VS Current LiabilitesNURO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for NURO have decreased strongly by -565.02% in the last year.
NURO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.40%.
The Revenue for NURO have been decreasing by -18.18% on average. This is quite bad
EPS 1Y (TTM)-565.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-254.97%
Revenue 1Y (TTM)-41.4%
Revenue growth 3Y-7.18%
Revenue growth 5Y-18.18%
Sales Q2Q%-51.06%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NURO Yearly Revenue VS EstimatesNURO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
NURO Yearly EPS VS EstimatesNURO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NURO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NURO Price Earnings VS Forward Price EarningsNURO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NURO Per share dataNURO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NURO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROMETRIX INC

NASDAQ:NURO (2/21/2025, 8:00:01 PM)

4.3875

-0.03 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-20 2025-02-20
Earnings (Next)05-13 2025-05-13
Inst Owners10.91%
Inst Owner Change-75.04%
Ins Owners14.78%
Ins Owner Change2.08%
Market Cap8.95M
Analysts82.86
Price TargetN/A
Short Float %0.16%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.38
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-4.59
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.3
FCFYN/A
OCF(TTM)-3.28
OCFYN/A
SpS1.85
BVpS7.83
TBVpS7.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.65%
ROE -48.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.56%
FCFM N/A
ROA(3y)-19.18%
ROA(5y)-27.69%
ROE(3y)-20.41%
ROE(5y)-50.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.03%
GM growth 5Y7.84%
F-Score2
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.88
Quick Ratio 12.7
Altman-Z -13.52
F-Score2
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)177.32%
Cap/Depr(5y)114.73%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-565.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-254.97%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-41.4%
Revenue growth 3Y-7.18%
Revenue growth 5Y-18.18%
Sales Q2Q%-51.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.93%
OCF growth 3YN/A
OCF growth 5YN/A